Global Automated Breast Ultrasound Systems (ABUS) Market - 2023-2030

Global Automated Breast Ultrasound Systems (ABUS) Market - 2023-2030

Market Overview

The global automated breast ultrasound systems market size was valued at US$ 14,24 million in 2023 and is estimated to reach US$ 2452 million by 2030, growing at a CAGR of 12.4% during the forecast period (2023-2030).

A more popular technique, Automated Breast Ultrasound (ABUS), can detect up to 30% more tumors in women with dense breast tissue (more glandular or fibrous than fatty), even if it is the only extra risk factor. Women with denser breasts may make mammography insufficient and can employ ABUS to discover more malignancies. No ionizing radiation is used during ultrasound procedures, and ABUS is a quick, painless, and efficient approach to photographing dense breasts.

Market Dynamics

The major factors driving the global Automated breast ultrasound systems market rising prevalence of breast cancer worldwide is the most significant driving factor of the market, as increasing technological advancements in automated breast ultrasound systems and rising awareness regarding breast cancer favorable government initiatives.

The rising prevalence of breast cancer worldwide is the most significant driving factor in the market.

According to WHO, in the glandular tissue of the breast, breast cancer begins in the living cells (epithelium) of the ducts (85%) or lobules (15%). The malignant development is initially restricted to the duct or lobule, where it often exhibits no symptoms and has a low risk of spreading. 684,000 people worldwide died in 2020 due to breast cancer, which affected 2.3 million women. The most common cancer globally as of the end of 2020 was breast cancer, diagnosed in 7.8 million women in the previous five years. Breast cancer is the form of cancer that results in the most lost disability-adjusted life years (DALYs) for women globally. Breast cancer occurs in every nation of the world in women at any age after puberty but with rising rates in later life.

The American Cancer Society predicts that in 2022, there will be about 287,840 new cases of invasive breast cancer in women, about 51,400 new instances of ductal carcinoma in situ (DCIS), and about 43,250 new cases of breast cancer-related deaths in women. Breast cancer is more common in women in their middle years and older. The typical age at breast cancer diagnosis is 62 years old. The average age at which breast cancer in women is found is therefore 62 years of age or less. Breast cancer diagnoses in women under 45 are incredibly uncommon.

The automated breast ultrasound system's high price will hamper the market’s growth.

The application of automated breast ultrasound imaging systems has been constrained by severe rules in a number of nations. Additionally, the high cost of automated breast ultrasound systems (ABUS) compared to traditional cancer screening methods is anticipated to restrain market expansion.

COVID-19 Impact Analysis

Infectious disease frequency increased in terms of the severity and rate of dissemination with the beginning of the COVID-19 pandemic. During the early stages of the global pandemic, the number of patients infected with the COVID-19 virus increased. To decrease and control different infection transmission, hospitals adopted emergency protocols as a top priority. This led to a decline in elective procedures that needed ultrasound screening. The use of X-rays, CT scans, and ultrasounds for emergency procedures that needed imaging services increased despite a reduction in elective ultrasound treatments. The adoption of ultrasound equipment for specialized diagnostics, notably for kidneys and lungs, is anticipated to increase due to COVID-19's long-term effects. The number of ultrasound operations for lungs exhibited a rising trend during the early stages of the pandemic.

Segment Analysis

The hospital’s segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

ABUS implementation is progressively gaining momentum in more hospitals to meet the patients' diagnostic demands. The demand for ABUS in these healthcare settings will be driven by rising cancer screening test usage among young and middle-aged women. Hospitals are installing ABUS to provide safer diagnostic choices because pregnant women cannot get mammography due to the radiation danger.

Breast cancer surgery involves operating to remove the tumor, which is a crucial part of treatment for the disease. Breast cancer surgery can be used either on its own or in conjunction with other therapies, such as chemotherapy, hormone therapy, targeted therapy, and radiation therapy, administered in a hospital setting under the guidance of a qualified doctor.

Each year, more than 100,000 American women get a mastectomy. Although it is frequently done to treat breast cancer, it is occasionally done to lower the chance of developing breast cancer. Because procedures must be performed in hospitals under the supervision of doctors, the hospital sector drives the market. Compared to general or specialty hospitals, teaching hospitals in several affluent nations have seen a dramatic increase in demand for various treatment modalities. However, the number of new hospitals in developing nations in North America has sharply increased. Imaging modalities typically have their room in new hospitals. Rising competition and rising demand for top-notch medical care are the two main reasons predicted to drive segment expansion.

Geographical Analysis

North America holds the largest market share in the global automated breast ultrasound systems market.

According to the American Society of Cancer, about 281,550 new breast cancer cases will be discovered in women in 2021, and 43,600 women will pass away from the disease. The prevalence of breast cancer is rising, increasing the need for cutting-edge breast imaging equipment and support for efficient therapies. The ABUS market in the U.S. will grow as government campaigns to inform and educate women about breast cancer and the value of screening increase. According to the Breast Cancer Organization, 1 in 8 (or around 13%) American women will eventually develop invasive breast cancer.

In the United States, women are anticipated to receive diagnoses for 287,840 new instances of invasive breast cancer and 51,500 new cases of non-invasive (in situ) breast cancer in 2022. In 2022, it's anticipated that 2,710 new instances of invasive breast cancer will be found in men. About 1 in 833 men may develop breast cancer in their lives. In the U.S., more than 3.8 million women have had breast cancer in the past as of January 2022. Women who have completed treatment and those who are presently receiving it are included. Several foundations in the United States have launched awareness programs, including the Susan Komen Foundation, the National Breast Cancer Foundation, and the American Society of Cancer's National Breast Cancer Awareness (NBCA) month. These will benefit the need for automated breast ultrasonography systems for detecting breast cancer in breast tissue with dense cellularity.

Competitive Landscape

The Automated breast ultrasound systems market is moderately competitive with local and global companies’ presence GE Healthcare, Hitachi, Ltd, Koninklijke Philips N.V., Siemens AG , SonoCiné Inc, Qview Medical, Hologic Inc, Volpara Solutions Limited, Delphinus Medical Technologies, Inc., Nova Medical Inc and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in December 2022, Koios DS, a software platform powered by artificial intelligence (AI) and shown to effectively diagnose thyroid and breast malignancies in ultrasound tests, has received CE Marking under the EU MDR, according to Koios Medical, a pioneer in the field of cancer diagnostics using ultrasound. The innovative dual-diagnosis method, developed utilizing data from a global network of 55 sites, speeds up interpretation, automates reporting, and shortens the time it takes to administer medication while eliminating unnecessary surgery

General Electric Company.

Overview: E Healthcare, a division of General Electric Company, is a global provider of medical devices that creates, develops, produces, and sells diagnostic imaging and clinical systems, as well as a variety of healthcare IT solutions, products and services for drug discovery, biopharmaceutical production, and cellular technologies. Additionally, GE Healthcare offers services including computerized data management, remote diagnostic and repair services for medical equipment made by the business and others, performance enhancement and performance solutions services, and other services.

Product Portfolio

Invenia ABUS 2.0: One of the biggest widespread risk factors for getting breast cancer is having thick breasts, which affects about 40% of women. The clinical data supporting the use of ultrasonography to detect tiny, node-negative, invasive tumors that mammography misses is emerging. For dense breast imaging in the screening context, Invenia ABUS 2.0 supplemental imaging is designed.

The global automated breast ultrasound systems market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.